比较C反应蛋白与白蛋白比值和格拉斯哥预后评分对弥漫大B细胞淋巴瘤患者预后判断的价值

Comparison of the Prognostic Value of C-Reactive Protein to Albu-min Ratio and Glasgow Prognostic Score in Patients with Diffuse Large B-Cell Lymphoma

目的:探讨并比较基于C反应蛋白(CRP)和白蛋白(ALB)的两种预测模型——CRP与ALB比值(CAR)和格拉斯哥预后评分(GPS)——在新诊断弥漫大B细胞淋巴瘤(DLBCL)患者预后评估中的价值。方法:回顾性分析本院2014年5月至2022年1月收治的初诊DLBCL患者的资料,纳入至少完成4个周期R-CHOP或R-CHOP样方案化疗,且临床、实验室检查数据以及随访资料均完整的111例患者。根据患者治疗前CAR及随访截止时的生存状态绘制受试者工作特征曲线(ROC),初步判断CAR对疾病进展和生存结局的预测价值,进一步分析CAR与患者基线临床、实验室特征的关系,并比较不同CAR、GPS分组患者的无进展生存期(PFS)和总生存期(OS),采用单因素和多因素COX风险比例回归模型分析影响疾病预后的因素。结果:ROC曲线分析结果显示,CAR预测DLBCL患者PFS、OS的曲线下面积(AUC)分别为0.687(P=0.002),0.695(P=0.005),最佳截断值均为0.11;相较于低CAR(<0.11)组,高CAR(≥0.11)组患者具有更多的临床高危因素,包括年龄>60岁(P=0.025)、ECOG评分≥2分(P=0.004)、Lugano分期III-IV期(P<0.001)、non-GCB亚型(P=0.035)、乳酸脱氢酶升高(P<0.001)、结外病变数>1处(P=0.004)及IPI评分>2分(P<0.001)。对患者进行中期疗效评估,低CAR组患者的总有效率(ORR)及完全缓解率(CRR)均明显优于高CAR组(ORR:96.9%vs 80.0%,P=0.035;CRR:63.6%vs 32.5%,P=0.008)。中位随访24个月,低CAR组患者的中位PFS及OS均明显优于高CAR组(中位PFS:未达到vs 67个月,P=0.0026;中位OS:未达到vs 67个月,P=0.002),而GPS 0分、1分和2分3组患者的PFS(P=0.11)和OS(P=0.11)差异均不具有统计学意义。多因素分析显示,仅有性别为男性和IPI评分>2分是影响患者PFS和OS的独立危险因素。结论:CAR与DLBCL患者的疾病进展和生存显著相关;与GPS相比,CAR对患者的预后判断价值更大。

Objective:To compare the prognostic value of two predictive models based on C-reactive protein(CRP)and albumin(ALB),namely the CRP to ALB ratio(CAR)and the Glasgow prognostic score(GPS),in newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL).Methods:The data of newly diagnosed DLBCL patients admitted to our center from May 2014 to January 2022 were reviewed.A total of 111 patients who completed at least 4 cycles of R-CHOP or R-CHOP-like chemotherapy with detailed clinical,laboratory data and follow-up information were included.The receiver operating characteristic(ROC)curve was performed to evaluate the predictive value of pre-treatment CAR on disease progression and survival.Furthermore,the association between CAR and baseline clinical,laboratory characteristics of patients was evaluated,and progression-free survival(PFS)and overall survival(OS)were compared between different CAR and GPS subgroups.Finally,the univariate and multivariate COX propor tional hazard regression models were used to analyze the factors affecting disease outcomes.Results:ROC curve showed that the area under the curve(AUC)of CAR predicting PFS and OS in DLBCL patients was 0.687(P=0.002)and 0.695(P=0.005),respectively,with the optimal cut-off value of 0.11 for both predicting PFS and OS.Compared with the lower CAR(<0.11)group,the higher CAR(≥0.11)group had more clinical risk factors,including age>60 years(P=0.025),ECOG score≥2(P=0.004),Lugano stage III-IV(P<0.001),non-germinal center B-cell-like(non-GCB)subtype(P=0.035),elevated lactate dehydrogenase(LDH)(P<0.001),extranodal involved site>1(P=0.004)and IPI score>2(P<0.001).The interim response evaluation of patients showed that the overall response rate(ORR)and complete response rate(CRR)in the lower CAR group were both significantly better than those in the higher CAR group(ORR:96.9%vs 80.0%,P=0.035;CRR:63.6%vs 32.5%,P=0.008).With a median follow-up of 24 months,patients with lower CAR had significantly longer median PFS and OS than those with higher CAR(median PFS:not reached vs 67 months,P=0.0026;median OS:not reached vs 67 months,P=0.002),while there was no statistical difference in PFS(P=0.11)and OS(P=0.11)in patients with GPS of 0,1,and 2.Multivariate Cox regression analysis indicated that only sex(male)and IPI score>2 were independent risk factors for both PFS and OS.Conclusion:CAR is significantly correlated with disease progression and survival in DLBCL patients;And compared with GPS,CAR has more advantages in predicting disease outcomes in DLBCL patients.